Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.60 |
| ▸ | NPC1 | O15118 | 12/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | PKM | P14618 | 5/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | SCD | O00767 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845946 | 0.93 | RAB9A (0.60) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1201180 | 0.91 | RAB9A (0.49) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1201545 | 0.90 | RAB9A (0.50) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1201612 | 0.87 | TOP1 (0.52) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1201986 | 0.87 | RAB9A (0.52) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1201677 | 0.86 | NPC1 (0.57) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13572153 | 0.84 | RAB9A (0.54) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1201768 | 0.84 | RAB9A (0.46) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2131843 | 0.83 | RAB9A (0.47) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1202206 | 0.83 | NPC1 (0.56) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | claimed |
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | RAB9A 2719/4885NPC1 188/4885KMT2A 4094/4885 |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | BACE1, BACE2, APP | RAB9A 2474/4885NPC1 190/4885KMT2A 4117/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | RAB9A 2719/4885NPC1 188/4885KMT2A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.